BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32643493)

  • 1. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
    Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
    J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status.
    Hart A; Ahn YS; Watson C; Skeans M; Barlev A; Thompson B; Dharnidharka VR
    J Med Econ; 2021; 24(1):620-627. PubMed ID: 33851571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
    Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
    Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
    J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
    [No Abstract]   [Full Text] [Related]  

  • 6. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
    Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
    J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 11. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
    Hagiwara M; Sharma A; Chung KC; Delea TE
    J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis.
    Bonafede M; Anaissie E; Evans K; Itzler R
    BMC Health Serv Res; 2021 Oct; 21(1):1125. PubMed ID: 34666775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding healthcare burden and treatment patterns among young adults with schizophrenia.
    Huang A; Amos TB; Joshi K; Wang L; Nash A
    J Med Econ; 2018 Oct; 21(10):1026-1035. PubMed ID: 30001651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care resource utilization and costs of recurrent
    Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
    J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
    [No Abstract]   [Full Text] [Related]  

  • 16. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 17. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database.
    Lee CC; Hsu TC; Kuo CC; Liu MA; Abdelfattah AM; Chang CN; Yao M; Li CC; Wu KH; Chen TC; Gau JP; Wang PN; Liu YC; Chiou LW; Lee MY; Li SS; Chao TY; Jou ST; Chang HH
    Oncologist; 2021 Nov; 26(11):e2034-e2041. PubMed ID: 34506688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence and Features of Lymphoid Proliferation and Lymphomas after Solid Organ or Hematopoietic Stem Cell Transplantation in a National Database Cohort.
    Hahn SM; Lee M; Hyun J; Lim S; Kang JM; Ahn JG; Joo DJ; Jung I; Ihn K
    Cancer Res Treat; 2024 Jan; 56(1):305-313. PubMed ID: 37475137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.